When was PAQ founded?

PAQ was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is PAQ located?

PAQ is headquartered in Cambridge, United States. It is registered at 625 Mass Ave. Office 02-146 Cambridge, MA, 02139, USA.

Is PAQ a funded company?

PAQ is a funded company, having raised a total of $111M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2020.

When was the latest funding round of PAQ?

PAQ's latest funding was a $***** Series B round on Jan 26, 2026, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.43B in funding in 2026 to date.

Where does PAQ rank among its competitors?

PAQ ranks 27th amongst 455 active competitors, of which 161 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of PAQ?

PAQ's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Among them, Alchemab secured the most recent funding round in July, 2026.

PAQ - 2026 Company Profile, Team, Funding & Competitors

PAQ is a series B company based in Cambridge (United States), founded in 2020 by Boxun Lu and Huaixiang Hao. It operates as a Developer of small molecule therapeutics for neurodegenerative disease. PAQ has raised $111M in funding from investors like MRLV, Sherpa Healthcare Partners and Bayland Capital. The company has 455 active competitors, including 161 funded and 80 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Regenxbio.

Company Details

Developer of small molecule therapeutics for neurodegenerative disease. The company offers autophagosome-tethering compounds that enhances the degradation of disease-causing protein and non-protein targets.

Website: www.paqtx.com
Email ID: *****@paqtx.com
Phone Number: +1 **********
Registered Address: 625 Mass Ave. Office 02-146 Cambridge, MA, 02139, USA

Key Metrics

Founded Year

2020

Location

Cambridge, United States

Stage

Series B

Total Funding

$111M in 4 rounds

Latest Funding Round

Series B, Jan 26, 2026, $*****

Investors

MRLV & 9 more

Ranked

27^th among 455 active competitors

Similar Companies

Denali Therapeutics & 565 more

View PAQ's full profile

PAQ is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PAQ Therapeutics Inc CIN: 85-2211089 , United States, Active	Jul 26, 2020	-	6 (As on Dec 31, 2021)	-

PAQ has raised a total funding of $111M over 4 rounds. Its first funding round was on 2020. PAQ has 10 institutional investors.

Here is the list of recent funding rounds of PAQ:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 26, 2026	5653132	Series B	3150427	9483625	2517037	7910252
May 06, 2025	9527235	Series B	8203312	9824642	1769327	Johnson & Johnson Innovation & 3 more
Jul 15, 2021	7135928	Series A	2851414	7761789	Sherpa Healthcare Partners	Huagai Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of PAQ's funding rounds and investors

The founders of PAQ are Boxun Lu and Huaixiang Hao.

Here are the details of PAQ's key team members:

Boxun Lu: Co-Founder of PAQ.
Contact Info: 1 email address
Huaixiang Hao: Co-Founder of PAQ.
Contact Info: 1 email address

View details of PAQ's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PAQ include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of PAQ, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	67/100
5th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
6th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	ATW Partners, Sanofi & 6 others	65/100
7th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	65/100
8th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
9th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	64/100
10th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	63/100
27th	PAQ 2020, Cambridge (United States), Series B	Developer of small molecule therapeutics for neurodegenerative disease	$111M	MSA Capital, Sherpa Healthcare Partners & 8 others	58/100